JP2020502130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502130A5 JP2020502130A5 JP2019531797A JP2019531797A JP2020502130A5 JP 2020502130 A5 JP2020502130 A5 JP 2020502130A5 JP 2019531797 A JP2019531797 A JP 2019531797A JP 2019531797 A JP2019531797 A JP 2019531797A JP 2020502130 A5 JP2020502130 A5 JP 2020502130A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- conjugate
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C[C@](C(N1[C@@](*)CC(*)(*)C1)=O)NC(c1c(*)c(*)nc(CN*)c1*)=O Chemical compound C[C@](C(N1[C@@](*)CC(*)(*)C1)=O)NC(c1c(*)c(*)nc(CN*)c1*)=O 0.000 description 5
- ZQYQPOLSGRRSNE-UHFFFAOYSA-N CC(CSSC)C=N Chemical compound CC(CSSC)C=N ZQYQPOLSGRRSNE-UHFFFAOYSA-N 0.000 description 1
- WIKGCXOVDRVFFT-UHFFFAOYSA-N CCC(C)C(C)NC(C1C(C)CCCC1)O Chemical compound CCC(C)C(C)NC(C1C(C)CCCC1)O WIKGCXOVDRVFFT-UHFFFAOYSA-N 0.000 description 1
- DPAVASXGSKZONM-UHFFFAOYSA-N CNCC(C(NC(CC(O)=O)C(NC(CS)C(O)=O)=O)=O)N Chemical compound CNCC(C(NC(CC(O)=O)C(NC(CS)C(O)=O)=O)=O)N DPAVASXGSKZONM-UHFFFAOYSA-N 0.000 description 1
- GNDCJIPICFVIRU-YFKPBYRVSA-N C[C@@H](O)OCN(C)C Chemical compound C[C@@H](O)OCN(C)C GNDCJIPICFVIRU-YFKPBYRVSA-N 0.000 description 1
- TZVRJNOXHZEKSA-UHFFFAOYSA-N FC1(F)[I]=CCCC1 Chemical compound FC1(F)[I]=CCCC1 TZVRJNOXHZEKSA-UHFFFAOYSA-N 0.000 description 1
- UPUWPXFXOFLTKV-UHFFFAOYSA-N NCCC(CC1)=CCC1O Chemical compound NCCC(CC1)=CCC1O UPUWPXFXOFLTKV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434380P | 2016-12-14 | 2016-12-14 | |
| US62/434,380 | 2016-12-14 | ||
| US201762575050P | 2017-10-20 | 2017-10-20 | |
| US62/575,050 | 2017-10-20 | ||
| PCT/US2017/065995 WO2018111989A1 (en) | 2016-12-14 | 2017-12-13 | Fibroblast activation protein (fap)-targeted imaging and therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502130A JP2020502130A (ja) | 2020-01-23 |
| JP2020502130A5 true JP2020502130A5 (enExample) | 2021-01-28 |
| JP7162592B2 JP7162592B2 (ja) | 2022-10-28 |
Family
ID=62559225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531797A Active JP7162592B2 (ja) | 2016-12-14 | 2017-12-13 | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20200237936A1 (enExample) |
| EP (1) | EP3555627B1 (enExample) |
| JP (1) | JP7162592B2 (enExample) |
| CN (2) | CN110291401B (enExample) |
| ES (1) | ES2972577T3 (enExample) |
| WO (1) | WO2018111989A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200237936A1 (en) | 2016-12-14 | 2020-07-30 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
| WO2019083990A2 (en) | 2017-10-23 | 2019-05-02 | The Johns Hopkins University | IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α) |
| JP2021506972A (ja) | 2017-12-15 | 2021-02-22 | プラクシス バイオテック エルエルシー | 線維芽細胞活性化タンパク質の阻害剤 |
| US20210038749A1 (en) * | 2018-02-06 | 2021-02-11 | Universität Heidelberg | Fap inhibitor |
| WO2019154859A1 (en) * | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
| US20210308267A1 (en) * | 2018-08-07 | 2021-10-07 | Purdue Research Foundation | Rejuvenation of car t cell |
| WO2020081522A1 (en) * | 2018-10-17 | 2020-04-23 | Purdue Research Foundation | Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis |
| WO2020132661A2 (en) * | 2018-12-21 | 2020-06-25 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| EP3997103B9 (en) | 2019-07-08 | 2025-02-26 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| CN114340610A (zh) * | 2019-07-22 | 2022-04-12 | 普渡研究基金会 | 多价成纤维细胞靶向剂及使用方法 |
| US20220409747A1 (en) * | 2019-09-17 | 2022-12-29 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases |
| WO2021155288A1 (en) * | 2020-01-31 | 2021-08-05 | Philip Stewart Low | Fibroblast activation protein (fap) - targeted antifibrotic therapy |
| PL3891138T3 (pl) | 2020-02-12 | 2022-05-02 | Philochem Ag | Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniu |
| PE20230490A1 (es) | 2020-03-24 | 2023-03-23 | Tufts College | Agentes para obtencion de imagenes y radiofarmacos dirigidos a la fap, y usos relacionados con los mismos |
| US20230158153A1 (en) * | 2020-04-09 | 2023-05-25 | Purdue Research Foundation | Pi3 kinase inhibitors and uses thereof |
| EP4147053B1 (en) | 2020-05-07 | 2026-01-28 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| KR20230121800A (ko) * | 2020-12-17 | 2023-08-21 | 트러스티즈 오브 터프츠 칼리지 | Fap-활성화된 래디오테라노스틱스, 및 이와 관련된용도 |
| CN114790195B (zh) * | 2020-12-21 | 2024-05-17 | 苏州药明博锐生物科技有限公司 | 成纤维细胞活化蛋白抑制剂 |
| EP4043452A1 (en) | 2021-02-12 | 2022-08-17 | Philochem AG | Bivalent fibroblast activation protein ligands for targeted delivery applications |
| AU2022219525B2 (en) * | 2021-02-12 | 2026-02-26 | Philochem Ag | Bivalent fibroblast activation protein ligands for targeted delivery applications |
| EP4308110A4 (en) * | 2021-03-16 | 2025-06-18 | Purdue Research Foundation | Compounds targeting fibroblast-activation protein and methods of use thereof |
| KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
| US20240207292A1 (en) * | 2021-03-24 | 2024-06-27 | Trustees Of Tufts College | Boronic acid compounds, compositions and methods |
| AU2022275579C1 (en) * | 2021-05-19 | 2024-08-22 | Ferronova Pty Ltd | Mapping nanoparticles |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| CN113521313A (zh) * | 2021-07-22 | 2021-10-22 | 戴格普瑞生物科技(苏州)有限公司 | 靶向造影剂、产品、制备方法及应用 |
| CN117460826A (zh) * | 2021-09-14 | 2024-01-26 | 菲柏生物医学技术（广州）有限公司 | 靶向FAP阳性细胞的siRNA缀合物及其药物组合物和应用 |
| KR20240093543A (ko) | 2021-10-04 | 2024-06-24 | 필로켐 아게 | 방사성 표지된 섬유모세포 활성화 단백질 리간드 |
| AU2022380909A1 (en) * | 2021-11-03 | 2024-06-06 | Adcentrx Therapeutics Inc. | Drug conjugates and methods of preparing and using the same |
| US20250177582A1 (en) | 2022-01-30 | 2025-06-05 | Philochem Ag | High-affinity ligands of fibroblast activation protein for targeted delivery applications |
| CN114214061B (zh) * | 2022-02-22 | 2022-05-17 | 北京大学 | 一种聚乙二醇修饰的两性离子化荧光探针、制剂及其应用 |
| WO2024052333A1 (en) | 2022-09-06 | 2024-03-14 | Philochem Ag | Multivalent fibroblast activation protein ligands for targeted delivery applications |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| CN120282804A (zh) | 2022-09-23 | 2025-07-08 | 核素迪姆股份公司 | 高纯度铜放射性药物组合物及其诊断和治疗用途 |
| WO2024102956A1 (en) * | 2022-11-09 | 2024-05-16 | Purdue Research Foundation | Keto-amide-based fibroblast activation protein-targeted ligand linked to an imaging or therapeutic agent, compositions and methods of use |
| EP4711362A1 (en) * | 2023-05-08 | 2026-03-18 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Ligand targeting fibroblast activation protein |
| CN116621823B (zh) * | 2023-07-06 | 2023-10-31 | 南京诺源医疗器械有限公司 | 诊断转移淋巴结近红外荧光示踪剂、合成方法及应用 |
| AU2024334645A1 (en) | 2023-08-31 | 2026-02-26 | Stichting Radboud Universitair Medisch Centrum | Endometriosis tracer |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5767242A (en) | 1994-04-20 | 1998-06-16 | Boehringer Ingelheim Int'l Gmbh | Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| US5851775A (en) | 1997-03-20 | 1998-12-22 | Johns Hopkins University | β-catenin, Tcf-4, and APC interact to prevent cancer |
| US20020004490A1 (en) | 1999-04-12 | 2002-01-10 | Dean Nicholas M. | Antisense modulation of Fas mediated signaling |
| AU3357299A (en) | 1998-03-20 | 1999-10-11 | Sloan-Kettering Institute For Cancer Research | Use of dipeptidyl peptidase (dpp4) for suppressing the malignant phenotype of cancer cells |
| EP0953639A1 (en) * | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| GB9827430D0 (en) | 1998-12-11 | 1999-02-03 | Ludwig Inst Cancer Res | Differential expression in primary breast cancer |
| CA2391534A1 (en) * | 1999-11-15 | 2001-05-25 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| EP1268550A2 (en) | 2000-03-17 | 2003-01-02 | Boehringer Ingelheim Pharma KG | Human fap-alpha-specific antibodies |
| US20090010919A1 (en) | 2004-07-29 | 2009-01-08 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated With Fibroblast Activation Protein (Fap) |
| US7374898B2 (en) | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
| US20090238862A1 (en) | 2004-10-27 | 2009-09-24 | Wen-Tien Chen | Methods and Compositions for Seprase Inactivation |
| AU2006246719A1 (en) | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| AU2006264305B2 (en) | 2005-07-05 | 2012-07-05 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein alpha |
| EP1760076A1 (en) | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| US8067248B2 (en) | 2005-12-14 | 2011-11-29 | Luwig Institute for Cancer Research | Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein |
| US20100047170A1 (en) | 2006-01-05 | 2010-02-25 | Denmeade Samuel R | Peptide Prodrugs |
| CA2658331A1 (en) | 2006-06-07 | 2007-12-21 | Patrick A. Mckee | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use |
| DK2035581T3 (da) | 2006-06-21 | 2012-10-08 | Scripps Research Inst | Dna-sammensætning mod tumorstromaantigen fap og fremgangsmåder til anvendelse deraf |
| DE602006015180D1 (de) | 2006-07-25 | 2010-08-12 | Pasteur Institut | Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie |
| BRPI0716368A2 (pt) | 2006-08-29 | 2013-10-01 | Molecular Insight Pharm Inc | porÇÕes de radioimageamento acopladas a porÇÕes de ligaÇço Á peptidase para imageamento de tecidos e àrgços que expressam peptidases |
| US20100184706A1 (en) | 2007-03-20 | 2010-07-22 | Bachovchin William W | Fap-activated chemotherapeutic compounds, and methods of use thereof |
| EP2139337A4 (en) | 2007-03-20 | 2012-09-19 | Tufts College | FIBROBLAST ACTIVATION PROTEIN INHIBITOR AND METHODS OF USE THEREOF |
| PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
| EP3542801A1 (en) | 2007-08-17 | 2019-09-25 | Boehringer Ingelheim International GmbH | Purin derivatives for use in the treatment of fap-related diseases |
| ES2372442T3 (es) | 2007-12-10 | 2012-01-19 | F. Hoffmann-La Roche Ag | Seprasa como marcador para cáncer. |
| WO2009139915A2 (en) | 2008-05-15 | 2009-11-19 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
| EP3501384B1 (en) * | 2008-05-20 | 2024-07-17 | University Health Network | Method for fluorescence-based imaging and monitoring |
| BRPI0919818A2 (pt) | 2008-09-25 | 2019-09-24 | Molecular Insight Pharm Inc | inibidores de seprase seletivos |
| US20120053222A1 (en) | 2009-01-23 | 2012-03-01 | Mark Gorrell | Novel Metabolic Disease Therapy |
| US10815517B2 (en) | 2009-04-28 | 2020-10-27 | Roche Diagnostics Operations, Inc. | Use of DPPIV/seprase as a marker for cancer |
| WO2011040973A2 (en) * | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof |
| JP2013506664A (ja) | 2009-10-02 | 2013-02-28 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド | 抗線維芽細胞活性化タンパク質抗体並びにその方法及び使用 |
| EP2397466B1 (en) | 2010-06-15 | 2012-11-28 | Centre National De La Recherche Scientifique CNRS | X-ray and gamma-photon activatable organic compounds, their preparation and their uses |
| WO2012025633A1 (en) | 2010-08-27 | 2012-03-01 | University Of Zurich | A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases |
| JP6207509B2 (ja) | 2011-08-30 | 2017-10-04 | トラスティーズ オブ タフツ カレッジ | 固形腫瘍を治療するためのｆａｐ活性化プロテアソーム阻害剤 |
| EP2804859B1 (en) | 2012-01-17 | 2019-06-12 | Universiteit Antwerpen | Novel fap inhibitors |
| WO2013166438A1 (en) | 2012-05-04 | 2013-11-07 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of prolyl oligopeptidase and fibroblast activation protein and methods of use |
| EP2866842A1 (en) | 2012-06-29 | 2015-05-06 | GE Healthcare UK Limited | Imaging fibrosis |
| US20150202218A1 (en) | 2012-08-02 | 2015-07-23 | Trustees Of Tufts College | Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections |
| AR092745A1 (es) * | 2012-10-01 | 2015-04-29 | Univ Pennsylvania | Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer |
| WO2014072465A1 (en) | 2012-11-09 | 2014-05-15 | Roche Diagnostics Gmbh | In vitro capture and analysis of circulating tumor cells |
| US9402888B2 (en) | 2013-03-14 | 2016-08-02 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancer |
| JP6192799B2 (ja) * | 2013-03-15 | 2017-09-06 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | 腫瘍の標的画像化に使用される化合物にコンジュゲートしているアミノ酸連結基の合成および組成物 |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| WO2014167083A1 (en) | 2013-04-12 | 2014-10-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the risk of developing a colonic neoplasia |
| MY176175A (en) | 2013-05-13 | 2020-07-24 | Vision Global Holdings Ltd | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| CN103267852B (zh) | 2013-05-15 | 2015-03-25 | 中国医学科学院北京协和医院 | 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途 |
| GB2538023A (en) | 2014-02-03 | 2016-11-02 | Philochem Ag | Targeted drug conjugates |
| IL291922B1 (en) | 2014-06-13 | 2026-01-01 | Tufts College | FAP-activated medical materials and related uses |
| US9737556B2 (en) | 2014-06-13 | 2017-08-22 | Trustees Of Tufts College | FAP-activated therapeutic agents, and uses related thereto |
| KR20170063946A (ko) | 2014-10-08 | 2017-06-08 | 에프. 호프만-라 로슈 아게 | Fap 및 dr5에 특이적인 이중특이성 항체와 화학요법제의 병용요법 |
| WO2016089879A1 (en) * | 2014-12-01 | 2016-06-09 | Endocyte, Inc. | Conjugates of garftase inhibitors |
| US20170369592A1 (en) | 2015-01-09 | 2017-12-28 | Mabimmune Diagostics AG | Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof |
| WO2016146174A1 (en) | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
| EP3281016A1 (en) | 2015-04-10 | 2018-02-14 | Applied Proteomics Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
| US20160303251A1 (en) * | 2015-04-17 | 2016-10-20 | Endocyte, Inc. | Conjugates of garftase inhibitors |
| KR20250057132A (ko) | 2016-03-22 | 2025-04-28 | 더 존스 홉킨스 유니버시티 | 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 |
| WO2017189569A1 (en) | 2016-04-25 | 2017-11-02 | Trustees Of Tufts College | Multimediator dpp4 and fap inhibitors, and uses related thereto |
| CN106046121B (zh) | 2016-06-20 | 2020-06-16 | 郑州大学 | 一种靶向fap的抗血管生成肽z-gp-v1及其应用 |
| CN105949282B (zh) | 2016-06-20 | 2020-06-16 | 郑州大学 | 一种靶向fap的抗血管生成肽z-gp-v2及其应用 |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| US20200237936A1 (en) | 2016-12-14 | 2020-07-30 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
| CN110461863A (zh) | 2017-04-04 | 2019-11-15 | 豪夫迈·罗氏有限公司 | 成纤维细胞活化蛋白(fap)识别的底物及其使用方法 |
| WO2019083990A2 (en) * | 2017-10-23 | 2019-05-02 | The Johns Hopkins University | IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α) |
| CN109796532B (zh) | 2017-11-17 | 2024-09-10 | 恺兴生命科技(上海)有限公司 | 靶向成纤维激活蛋白α的结合单元及其应用 |
| CN108152258A (zh) | 2017-12-13 | 2018-06-12 | 清华大学 | 一种检测待测溶液中氨基糖苷类抗生素的含量的方法 |
| JP2021506972A (ja) | 2017-12-15 | 2021-02-22 | プラクシス バイオテック エルエルシー | 線維芽細胞活性化タンパク質の阻害剤 |
| CN108333365B (zh) | 2018-01-24 | 2020-09-04 | 南开大学 | 金-长余辉纳米粒子免原位激发检测成纤维细胞激活蛋白 |
| WO2019154859A1 (en) | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
| WO2020081522A1 (en) | 2018-10-17 | 2020-04-23 | Purdue Research Foundation | Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis |
| GB201820320D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for FAPalpha |
| MX2021007948A (es) | 2019-01-04 | 2021-08-11 | Praxis Biotech LLC | Inhibidores de proteina de activacion de fibroblastos. |
| CN110368496B (zh) | 2019-07-11 | 2020-12-29 | 同济大学 | 成纤维细胞激活蛋白抑制剂在制备药物中的用途 |
| WO2021120526A1 (zh) | 2019-12-16 | 2021-06-24 | 四川大学华西医院 | 同时靶向间皮素和fap的双靶点嵌合抗原受体及其用途 |
| CN111235221B (zh) | 2020-01-22 | 2022-08-05 | 北京大学第一医院 | 一种fap抑制剂的活性检测方法 |
-
2017
- 2017-12-13 US US16/469,907 patent/US20200237936A1/en not_active Abandoned
- 2017-12-13 CN CN201780086490.3A patent/CN110291401B/zh active Active
- 2017-12-13 CN CN202310269637.XA patent/CN116474108A/zh active Pending
- 2017-12-13 ES ES17880889T patent/ES2972577T3/es active Active
- 2017-12-13 WO PCT/US2017/065995 patent/WO2018111989A1/en not_active Ceased
- 2017-12-13 EP EP17880889.5A patent/EP3555627B1/en active Active
- 2017-12-13 JP JP2019531797A patent/JP7162592B2/ja active Active
-
2021
- 2021-04-30 US US17/245,872 patent/US11872291B2/en active Active
- 2021-12-16 US US17/553,113 patent/US12397069B2/en active Active
-
2025
- 2025-08-04 US US19/289,533 patent/US20260048157A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502130A5 (enExample) | ||
| AU2016358441B2 (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| CN110291401B (zh) | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 | |
| CN105102003B (zh) | 吡咯并苯并二氮杂卓-抗psma抗体结合物 | |
| CN105102068B (zh) | 吡咯并苯并二氮杂卓-抗体结合物 | |
| CN105102004B (zh) | 吡咯并苯并二氮杂卓-抗cd22抗体结合物 | |
| CN104955485B (zh) | 吡咯并苯并二氮杂卓‑抗her2抗体结合物 | |
| JP2020502131A5 (enExample) | ||
| CN107057398B (zh) | 一种七甲川菁荧光染料及其肿瘤精准诊断和治疗的应用 | |
| RU2003137593A (ru) | Соединения на основе пептидов для направленной доставки к рецепторам интегринов | |
| CN105050661A (zh) | 吡咯并苯并二氮杂卓-抗体结合物 | |
| JP7184775B2 (ja) | 黄体化ホルモン放出ホルモン受容体（ｌｈｒｈ－ｒ）コンジュゲートおよびその使用 | |
| US12239707B2 (en) | Photodynamic compositions and methods of use | |
| CN111372609A (zh) | 声动力学疗法 | |
| JP2020109099A (ja) | 蛍光イメージングのためのｉｒ色素 | |
| CN109922834B (zh) | 用于治疗癌症的卟啉化合物和组合物 | |
| JP2019515880A5 (enExample) | ||
| JP2018512390A (ja) | Ｐｓｍａリガンド−チューブリシン化合物を用いた癌の処置方法 | |
| CN114945374A (zh) | 药物组合物和方法 | |
| JPWO2019244954A1 (ja) | ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン１０薬剤 | |
| US20220347306A1 (en) | Selective delivery of therapeutic and imaging agents | |
| EP3781194A1 (en) | Compositions and methods for the selective delivery of therapeutic and imaging agents | |
| JP2024518097A (ja) | 刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法 | |
| CA3104821C (en) | Photodynamic compositions and methods of use | |
| Wang et al. | A Near-Infrared Fluorogenic Spray Probe for Rapid and Wash-Free Intraoperative Nerve Imaging |